FierceBiotech Mar 9, 2026 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
Roche Media Mar 9, 2026 Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits - Fierce Biotech
Roche Media Mar 9, 2026 Roche’s prized breast cancer pill fails closely watched study - BioPharma Dive
Roche Media Mar 9, 2026 ZAWYA-PRESSR: Ministry of Health and Population and Roche Diagnostics sign MoU to advance digital pathology in Egypt - TradingView
Roche Media Mar 6, 2026 Roche, Zealand tout the tolerability of their amylin obesity drug - TechTarget
Roche Media Mar 6, 2026 Roche’s petrelintide shows promise in Phase II obesity trial - The Pharma Letter
FierceBiotech Mar 6, 2026 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug
Roche Media Mar 5, 2026 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug - Fierce Biotech
FierceBiotech Mar 4, 2026 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'